Preclinical models suggest that specific blockade of TNFR2 may significantly reduce inflammation and ameliorate signs of psoriatic diseases, while maintaining normal immune response in the host, including the ability to combat infection and cancer. In this article, M. Elaine Husni, MD, MPH, highlights her latest research and discusses her plans to use her new R01 grant to continue her translational work.
Translational work combining human plasma studies and previous mouse model data will enable identification of new, precise biomarkers and potential treatment pathways that may help pinpoint and treat RA and PsA patients at increased risk of CV disease.
Golimumab is safe and effective for treating PsA, according to the 24-week report of the GO-VIBRANT study.
Does the addition of intra-articular HA injections to PT have a synergistic effect in alleviating pain and reducing disability in patients with knee OA?
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Our findings reveal that bariatric surgery and the resulting massive weight loss have the potential to considerably improve health-related quality of life for patients suffering from OA for up to three years.
Subgroup analyses from the PRECISION trial allow rheumatologists to offer individualized treatment to OA and RA patients on chronic NSAIDs.
Orthopaedic surgeons at Cleveland Clinic will perform the first prospective, double-blind, randomized, placebo-controlled, multicenter feasibility study to examine the safety and efficacy of pulsed electromagnetic fields knee braces in the treatment of knee osteoarthritis.
The promise of drug-free RA remission is appealing, but many questions remain. Explore answers at Biologics Summit VII in April 2017.
Our laboratory tests whether aberrant levels of plasma and tissue L-arginine metabolites serve as an early, non-invasive predictor of CV disease in psoriatic patients.
Here’s why psoriatic arthritis is among the first clinical areas Cleveland Clinic’s collaborative Center for Clinical Genomics has chosen to focus on.